Effects of the COVID-19 pandemic on psychology and disease activity in patients with ankylosing spondylitis and rheumatoid arthritis

Şakir GICA1*, Yasemin AKKUBAK2, Zakire Kübra AKSOY3, Adem KÜÇÜK3, Erkan CÜRE4

1Department of Psychiatry, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
2Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Necmettin Erbakan University, Konya, Turkey
3Department of Rheumatology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
4Department of Internal Medicine, Ota Jinemed Hospital, İstanbul, Turkey

Background/aim: The COVID-19 outbreak is known to increase stress levels of most patients with chronic diseases. Patients with ankylosing spondylitis (AS) and rheumatoid arthritis (RA) are highly susceptible to environmental stress. In the current study, we aimed to determine how the COVID-19 pandemic psychologically affected patients with chronic progressive diseases such as AS and RA and the effects of these psychological factors on disease activity.

Materials and methods: Age and sex-matched patients with AS (n = 80), RA (n = 80), and healthy controls (n = 80) were included in the study. All participants were evaluated with the “Perceived COVID-19 Threat Form (PCTF)”, “Suicide-Ideation Scale (SIS)”, “Hospital Anxiety and Depression Scale (HADS)”, “The Ability to Cope with Trauma (PACT)”, and “Psychological General Well-Being Index (PGWB)” scales. BASDAI was used in patients with AS, and DAS28 was used in patients with RA to assess disease severity.

Results: Compared to healthy individuals, patients with RA and AS had lower PGWB scores and higher HADS depression and anxiety subscale scores. Almost all psychometric assessment test scores were worse in AS patients with high-disease activity compared to those in low-disease activity. PACT scores were higher in patients with moderate RA compared to patients with mild RA (p = 0.006). While a positive correlation was identified between BASDAI and most of the psychometric assessment test scores (r = 0.36 for PCTF, r = 0.53 for depressive scores, r = 0.54 for anxiety scores, r = 0.57 for suicidal ideation), DAS28 scores were found to be associated only with PACT total and PACT perceived forward-focused subscale scores (r = –.26 and r = .33, respectively).

Conclusion: Psychologically, AS and RA patients were found to be worse off compared to healthy controls. The perceived COVID threat and psychological status were associated with disease activity in AS, but not RA patients. Patients with chronic illnesses may be more vulnerable to the psychological effects of the pandemic, which can worsen disease activity.

Key words: COVID-19, ankylosing spondylitis, rheumatoid arthritis, psychological well-being, disease activity, coping ability

1. Introduction

Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are the two most common rheumatological diseases worldwide [1]. It is known that psychiatric symptoms such as depressive mood and anxiety are more widespread in patients with rheumatological diseases than healthy individuals [2–5]. According to data from the United States of America, the lifetime prevalence of psychiatric disorders in RA patients was 63.6% [6]. In a long-term comprehensive longitudinal Swedish cohort study, psychiatric symptoms/illnesses were reported to be more common in patients with AS compared to patients with RA [7]. A significant relationship was reported between psychiatric syndromes and disease activity scores such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), pain and fatigue in patients with AS [8]. Complaints of anxiety and depression are frequently encountered in these patients [9]. A significant relationship between the scale Disease Activity Score in 28 Joints (DAS28), as well as other disease activity scores and psychiatric syndromes such as anxiety and depression have also been reported in RA [10].

The novel coronavirus 2019 (COVID-19) outbreak, which started in Wuhan in January 2019 and then spread worldwide, has been declared a pandemic and its repercussions are continuing. Data from the COVID-19 outbreak as well as previous pandemics have shown that...
large-scale outbreaks have a wide spectrum of psychosocial effects. In particular, patients with chronic diseases are more susceptible to psychosocial stressors, both physically and psychologically. Symptoms of psychosocial effects such as intense stress, nervousness, anxiety, fear, complaints of depression, decreased tolerance, anger, post-traumatic stress disorder, and psychosomatic complaints are often observed [11,12,13]. Additionally, individuals may obtain incorrect information related to chronic diseases during the pandemic, both through social media and their relatives and friends. This may cause an increase in anxiety levels and a decrease in coping strategies to reduce psychological well-being overall [14].

Complaints such as depression, sleep disorders, loss of appetite, and fatigue, which are difficult to adapt to and make it harder to maintain social communication, can be seen more frequently in patients with chronic diseases [15]. Interestingly, the risk of COVID-19 was reported to not be higher in RA and AS patients with no effect on the clinical course of these diseases during the pandemic [16,17]. However, patients with rheumatological diseases, who are prone to psychological disorders, are likely to be easily psychologically affected by the COVID-19 outbreak. Recent studies have shown that patients with RA, axial spondyloarthritis, lupus, and Behçet Disease were severely affected by the COVID-19 pandemic [18–21].

In the current study, we aimed to determine how the COVID-19 pandemic psychologically affected patients with chronic progressive diseases, such as AS and RA and the effects of these psychological factors on disease activity.

2. Materials and methods
2.1. Participants
Age and gender-matched patients with AS (n=80), RA (n=80), and healthy volunteers (n=80) were recruited for the study. The AS and RA groups were comprised of patients who were followed up at the Necmettin Erbakan University, Meram Medical Faculty, Department of Rheumatology. Patients with AS were contacted by telephone first and related documents were sent to their smart-phones via online communication applications. We excluded patients with other co-morbid chronic diseases from the current study. Similarly, the healthy control group was reached via online communication applications. Relatives of patients with no chronic disease who applied to the internal medicine outpatient clinic were included in the healthy control group. Data from RA patients were obtained with face-to-face interviews at the hospital since blood analysis results were necessary to calculate DAS28 scores. Participants who were under 18 years old, over 70 years old, and with less than 5 years of formal education were not included in the study. Additionally, the data of participants who did not complete all psychometric assessment scales were excluded from the analysis. The sample size was calculated by evaluating the effect size as 0.25, α-err as 0.05, and power as 0.90 with G Power 3.1.9.2 [22,23].

2.2. Ethical approval
The Turkish Ministry of Health, General Directorate of Health Services approved the study protocol (Approval Date/Number: 29.04.2020/ŞAKİR GICA-2020-04-29-T16_26_23). The local Ethics Committee on human research also approved the study (IRB Date/Number: 08.05.2020/2020-2485). Prior to the start of the study, all participants received an informed consent form stating the details of the research, and participants who consented to volunteer approved this form. The participants were accepted to the study after they provided their written informed consent.

2.3. Data collection tools
Personal Information Form was used to obtain demographic information about the participants.

Perceived COVID-19 Threat Form (PCTF) was developed by Kavaklı et al [17]. The form has seven items and a five-point Likert type scale ranging from never (score of 1) to always (score of 5). The developers of this scale stated that the form has a one-factor structure according to parallel analysis. The form aims to measure the participants’ perceived COVID-19 threat levels; a higher total score corresponds to a higher perceived threat from the COVID-19 pandemic. Kavaklı et al. reported the Omega reliability score of the scale as .78 [24].

Suicide ideation Scale (SIS) is a self-reported test that was developed in 1989 by Levine et al. The SIS is comprised of 17 questions that are answered in a yes/no manner, and the total score of the scale varies between 0 and 17. A high score means pronounced suicidal ideation. Nesrin et al. performed the validity and reliability studies for the Turkish scale [25].

Hospital Anxiety and Depression Scale (HADS) was developed by Zigmond and Sinaith to determine risk groups by evaluating anxiety and depression in a brief time in people with physical illness. It is a self-reported scale comprising 17 questions and 2 sub-dimensions. Its validity and reliability in the Turkish have been conducted by Aydemir at al [26].

The Perceived Ability to Cope with Trauma scale (PACT) is a 5-point Likert-type self-reported scale developed by Bonanno et al. (2011) to test the perception of coping with trauma in life [27]. The Turkish form of the scale is comprised of 20 items and has a 2-factor structure. There are no inverse items on the scale. Cronbach’s alpha internal consistency coefficient was calculated as 0.79 for trauma focus, 0.90 for future focus, and 0.79 for the total scale. Ari et al. reported the validity and reliability of the scale in Turkish [28].
Psychological general well-being index score (PGWB) score is a self-reported test that was developed by Diener et al. The score is comprised of eight items that define important elements of human function from positive relationships to feelings of efficacy and a meaningful life [29]. The scores range from 8 (I do not agree with all items absolutely) to 56 (I agree with all items absolutely). A top score indicates the presence of psychological resources and powers in the patient. The adaptation of the scale into Turkish was carried out by Telef et al. [30].

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used in the clinical evaluation of AS patients and is comprised of 6 questions. The patient is asked to answer the questions by considering events during the past week [31] and scores the first five questions between 0 and 10 with 0 corresponding to “absent” and 10 corresponding to “very severe”. The BASDAI score is calculated by summing the average of the scores obtained from the fifth and sixth questions and the scores obtained from the first four questions and dividing the latter score by five. Akkoc et al. reported the validity and reliability study of the Turkish version of the scale [32].

Disease Activity Score-28 (DAS28) is used to evaluate the severity of RA by calculating the swollen, sensitive joint number, “Erythrocyte Sedimentation Rate (ESR)” and “Visual Analogue Scale (VAS)” data together. In some studies, “C-Reactive Protein (CRP)” is also used instead of ESR [33].

2.4. Procedure
After obtaining ethical approval, the data from the study participants were gathered online to keep social distance during the COVID-19 pandemic. All participants received an informed consent form stating the details about the study and individuals who volunteered to take part approved this form. Then, a questionnaire booklet was created with considerations of the order effect. The data of patients with RA were obtained with face-to-face interviews since data from blood analysis were needed to calculate the DAS28 score.

2.5. Statistical analysis
Descriptive variables are reported as mean ± SD, median (range), n, and percentage. To evaluate whether the variables had a normal distribution, visual (histogram and probability graphs) and analytical (Kolmogorov–Smirnov and Shapiro–Wilk) tests were conducted. The Kruskal–Wallis test was used for comparison of the suicidal ideation scale scores between the multiple independent groups. The level of statistical significance in nonparametric multiple comparisons was determined with the Bonferroni correction (p < 0.05 / number of comparisons). One-way ANOVA was used for statistical evaluation of the normally distributed numerical data between multiple independent groups. For one-way ANOVA, homogeneity was determined with Levene’s statistic test, followed by a post hoc least significant difference (LSD) test. The RA patients were divided into two groups: a remission or mildly active group (DAS28 < 3.2) and a moderate to high activity group (DAS28 ≥ 3.2) [34]. The AS patients were grouped into high disease activity score (BASDAI ≥ 4) and low-disease activity score (BASDAI < 4) according to the BASDAI scores [35]. Based on the parametric distribution of the data, psychometric assessment scales of remission/mild and moderate RA patients were compared with Student’s t-test and AS patients at remission or non-remission were compared with Mann–Whitney U test. Chi-square test and Fisher’s Exact test were used to compare categorical variables between the groups. If both variables fit the normal distribution, the relationship between the numerical variables was evaluated using Pearson correlation analysis, and if at least one of the variables did not fit the normal distribution, the variables were evaluated using Spearman correlation analysis. For statistical significance, a total type-1 error level of 5% was used.

3. Results
Comparative data on sociodemographic characteristics and clinical features of patients with AS, RA, and the healthy control group is shown in Table 1. The mean BASDAI score of patients with AS was found to be 5.3 ± 2.6, and the mean DAS28 score of RA patients was found to be 3.0 ± 0.9. The age and sex of the patient with AS, RA, and control groups were statistically similar. The disease duration in AS patients was 9.0 ± 7.0 years and the same in RA patients was 7.8 ± 6.9 years (p = 0.567). No significant difference was found between the groups in terms of the presence of psychiatric disorders, smoking, pain level, and regular exercise. The level of education was found to be lower in the RA patients compared to AS patients and the control group (p < 0.001). A significant difference in working status was found between the groups (p = 0.001).

A comparison of psychometric assessment scale scores of patients with AS, RA and the healthy control group is shown in Table 2. Compared to the control group, patients with RA or AS had lower PGWB scores, and higher HADS depression and anxiety subscale scores (p = 0.024 and p = 0.044 for RA patients; p = 0.001 and p = 0.044 for AS patients, respectively). There was no significant difference in PCTF, SIS, PACT trauma-focused coping scores between the groups. PACT perceived forward-focused subscale scores were significantly lower in RA patients compared to the control group and AS patients.

All psychometric assessment scales were found to be significantly different between AS patients with high-disease activity score and low-disease activity score except the PACT forward-focused sub-dimension. A significant
difference was identified only in the PACT total and PACT forward-focused sub-dimension scores between RA patients with mildly active or in remission versus RA patients with moderate to high active. The comparative psychometric assessment scale scores of AS and RA patients according to disease severity are shown in Table 3. The correlation analyses indicated the presence of a significant relationship between the BASDAI total score and scores of most of the psychometric assessment scales used. The DAS28 scores were found to be significantly associated only with PACT total and PACT perceived forward-focused subscales scores. Correlation analyses between the BASDAI/DAS28 and psychometric assessment scales are shown in Table 4. Patients with AS showed a negative correlation between PCTF scores and PGWB scores (r = –0.41, p < 0.001) and a positive correlation between PCTF and SIS, HADS-depression subscale, and HADS-anxiety subscale (r = 0.40, p < 0.001; r = 0.36, p = 0.001; r = 0.39, p < 0.001, respectively). However, no correlation was found between PCTF and PGWB scores in patients with RA. Nevertheless, similar to patients with AS, a positive correlation was found between PCTF

Table 1. Comparison of sociodemographic characteristics and clinical features of patients with AS, RA, and healthy control group.

|                      | Patients with AS (n = 80) | Patients with RA (n = 80) | Control (n = 80) | p value |
|----------------------|---------------------------|---------------------------|-----------------|---------|
| Age (years) (mean ± SD) | 41.5 ± 8.8                | 44.4 ± 9.0                | 42.4 ± 10.3     | 0.140   |
| Gender (M) (n, %)     | 42 (52.5%)                | 24 (30%)                  | 33 (41.25%)     | 0.149   |
| Disease duration (years) (median (min-max)) | 7.01–30                  | 5(0–37)                   | 0.158           |
| BASDAI score (median (min–max)) | 5.40 (0–10)              |                           |                 |         |
| DAS28 score           |                           |                           | 3.0 ± 0.9       |         |
| Pain levels (mean ± SD) | 5.4 ± .2.9                | 5.6 ± 2.8                 | 0.613           |
| Smoking (n, %)        |                           |                           |                 |         |
| High school and below | 49 (61.2%)                | 70 (89.7%)                | 0 (0%)          | <0.001* |
| College               | 31 (38.8%)                | 8 (10.3%)                 | 80 (100%)       |         |
| Unemployed            | 29 (36.25%)               | 47 (58.75%)               | 3 (3.75%)       | 0.001*  |
| Employed              | 37 (46.25%)               | 24 (30%)                  | 61 (76.25%)     |         |
| Temporary incapacity  | 4 (5%)                    | 3 (3.75%)                 | 9 (11.25%)      |         |
| Retired               | 10 (12.5%)                | 6 (7.5%)                  | 7 (8.75%)       |         |
| Married               | 70 (87.5%)                | 66 (82.5%)                | 68 (85%)        | 0.676   |
| Unemployed            | 14 (17.5%)                | 24 (30%)                  | 18 (22.5%)      | 0.464   |
| Employed              | 37 (46.25%)               | 24 (30%)                  | 61 (76.25%)     |         |
| Temporary incapacity  | 4 (5%)                    | 3 (3.75%)                 | 9 (11.25%)      |         |
| Retired               | 10 (12.5%)                | 6 (7.5%)                  | 7 (8.75%)       |         |
| None                  | 48 (60%)                  | 60 (75%)                  | 60 (75%)        | 0.975   |
| Depression            | 5 (6.25%)                 | 6 (7.5%)                  | 5 (6.25%)       |         |
| Anxiety               | 13(16.25%)                | 5 (6.25%)                 | 8 (10%)         |         |
| After any trauma      | 4(5%)                     | 2 (2.5%)                  | 4 (5%)          |         |
| Obsessive–compulsive disorder | 1 (1.25%)            | 0 (0%)                    | 0 (0%)          |         |
| Miscellaneous         | 9 (11.25%)                | 5 (6.25%)                 | 3 (3.75%)       |         |

*p < 0.05, One way ANOVA, Chi-Square and Mann–Whitney U tests were performed. AS: Ankylosing Spondylitis, RA: Rheumatoid Arthritis. M: Male, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, DAS28: Disease Activity Score-28.

a In post hoc analysis of education level between 3 independent group p < 0.001 for each analysis.

b p < 0.001, when healthy and patients with Ankylosing Spondylitis group were compared; p < 0.001, when healthy and patients with Rheumatoid Arthritis group were compared; p = 0.020, when patients with Ankylosing Spondylitis and Rheumatoid Arthritis group were compared.

c p = 0.749, when healthy and patients with Ankylosing Spondylitis group were compared; p = 0.002, when healthy and patients with Rheumatoid Arthritis group were compared; p = 0.001, when patients with Ankylosing Spondylitis and Rheumatoid Arthritis group were compared.
and SIS, HADS-depression subscale, and HADS-anxiety subscale ($r = 0.34$, $p = 0.003$; $r = 0.23$, $p = 0.005$; $r = 0.48$, $p < 0.001$, respectively) in patients with RA.

4. Discussion

A pandemic that has spread to large masses worldwide and has caused nearly 2 million deaths will inevitably have a psychological impact on many individuals, including patients with chronic diseases such as RA and AS. In the present study, we investigated the effect of the pandemic on the psychological status and relationship of the latter with disease activities in patients with RA and AS. When compared to healthy controls, we found that patients with RA as well as AS had low levels of well-being and high mental discomfort.

Table 2. Comparison of psychometric assessment scale results of the patients with AS and RA, and control groups.

|                          | Control (n=80) | Patients with AS (n=80) | Patients with RA (n=80) | p<sup>1</sup> | p<sup>2</sup> | p<sup>3</sup> | p<sup>4</sup> |
|--------------------------|---------------|-------------------------|-------------------------|--------------|--------------|--------------|--------------|
| PCTF (mean ± SD)         | 19.4 ± 5.6    | 20.5 ± 7.1              | 19.2 ± 6.5              | 0.429        | 0.284        | 0.908        | 0.242        |
| PGWB (mean ± SD)         | 45.7 ± 6.9    | 42.6 ± 10.0             | 42.1 ± 10.1             | 0.024*       | 0.024*       | 0.014*       | 0.819        |
| SIS (median [min-max])   | 1 (0–11)      | 2 (0–14)                | 2 (0–15)                | 0.215        | 0.141        | 0.118        | 0.881        |
| PACT (mean ± SD)         | 100.7 ± 14.4  | 96.5 ± 16.9             | 92.5 ± 17.5             | 0.008*       | 0.105        | 0.002*       | 0.131        |
| PACT trauma-focused coping (mean ± SD) | 63.8 ± 13.1 | 60.7 ± 14.5 | 59.7 ± 14.7 | 0.160 | 0.168 | 0.067 | 0.636 |
| PACT perceived forward-focused (mean ± SD) | 36.8 ± 7.1 | 35.7 ± 8.9 | 32.9 ± 10.5 | 0.020* | 0.439 | 0.007* | 0.050* |
| HADS depression (mean ± SD) | 5.0 ± 3.7 | 7.1 ± 4.7 | 7.2 ± 4 | 0.001* | 0.002* | 0.001* | 0.873 |
| HADS Anxiety (mean ± SD) | 6.1 ± 3.7 | 7.5 ± 4.4 | 7.8 ± 5.2 | 0.044* | 0.019* | 0.054 | 0.679 |

*<sup>p</sup> < 0.05, One way ANOVA and Kruskal–Wallis test were performed. For One-Way ANOVA test, homogeneity was determined with Levene Statistic test and LSD test was applied in post-hoc analysis.

p<sup>1</sup> p value of One way ANOVA or Kruskal–Wallis Test.

p<sup>2</sup> Healthy controls vs. patients with Ankylosing Spondylitis.

p<sup>3</sup> Healthy controls vs. patients with Rheumatoid Arthritis.

p<sup>4</sup> patients with Ankylosing Spondylitis vs. patients with Rheumatoid Arthritis.

Abbreviations: AS: Ankylosing spondylitis, RA: Rheumatoid Arthritis, PCTF: perceived COVID-19 threat form, PGWB: psychological general well-being index, SIS: suicide ideation scale, PACT: the perceived ability to cope with trauma scale, HADS: hospital anxiety and depression scale.

Table 3: Comparison of psychometric assessment scores of patients with AS and RA according to disease activity scores.

|                      | Ankylosing Spondylitis | Rheumatoid arthritis |
|----------------------|------------------------|----------------------|
|                      | Low-ASDAS Group (n=25) | High-ASDAS Group (n=55) | p     | Remitted or Mildly Active Group (n=45) | Moderate or High Active Group (n=34) | p     |
| PCTF                | 17 (7–35)              | 21 (7–35)            | 0.017* | 18.6 ± 6.9                | 20.2 ± 6.08                | 0.300 |
| PGWB                | 48 (8–56)              | 43 (17–56)           | 0.031* | 42.8 ± 9.8                | 41.1 ± 10.5                | 0.470 |
| SIS                 | 1 (0–6)                | 2 (0–14)             | 0.007* | 2 (0–12)                  | 2 (0–15)                  | 0.385 |
| PACT                | 104 (5–133)            | 96 (48–140)          | 0.030* | 87.9 ± 18.1               | 98.8 ± 14.8               | 0.006* |
| PACT trauma-focused coping | 71 (30–84)          | 59 (24–84)           | 0.005* | 57.2 ± 16.7               | 63.0 ± 11.0               | 0.091 |
| PACT perceived forward-focused | 34 (11–49)        | 36 (16–56)          | 0.259  | 30.7 ± 10.2               | 35.8 ± 10.3               | 0.035* |
| HADS depression      | 3 (0–17)               | 8 (1–18)             | <0.001* | 6.6 ± 4.0                 | 8.05 ± 3.9                | 0.135 |
| HADS Anxiety         | 4 (0–17)               | 8 (1–21)             | <0.001* | 6.8 ± 4.4                 | 8.4 ± 4.3                 | 0.119 |

*p<0.05, Student T and Mann–Whitney U tests were performed.

Abbreviations: ASDAS: Ankylosing spondylitis Disease Activity Score, PCTF: perceived COVID-19 threat form, PGWB: psychological general well-being index, SIS: suicide ideation scale, PACT: the perceived ability to cope with trauma scale, HADS: hospital anxiety and depression scale.
levels of depression; patients with RA had low ability to cope with trauma, while patients with AS had high anxiety levels. A statistically significant relationship was identified between disease activity and ability to cope with trauma, suicidal ideation, depression, and anxiety levels in patients with AS. AS patients with high disease-activity differ from AS patients with low-disease activity in all psychometric areas. In patients with RA, a significant relationship was identified only between disease activity and the ability to cope with trauma. The ability to cope with trauma of patients with moderate to high active RA was higher than patients with remitted or mildly active RA. We found a positive correlation between perceived COVID-19 threat and suicidal ideations, level of depression, and anxiety in both RA and AS patients. However, a strong correlation was identified between perceived COVID-19 threat and psychological well-being in patients with AS, but not in patients with RA.

Psychiatric disorders such as anxiety, depression, and stress can often be seen in patients with AS and RA [36,37] and can significantly reduce their quality of life by negatively affecting their day to day living [1]. However, psychiatric symptoms may differ in patients suffering from these diseases, and the prevalence of psychiatric symptoms may vary. Sundquist et al. reported that patients with AS had a higher prevalence of psychiatric symptoms compared to patients with RA [7]. In a German study, the frequency of depressive symptoms in patients with axial spondyloarthritis was found to be similar to patients with RA [38]. The HADS anxiety and depression scale scores of both RA and AS patients were reported to be higher than healthy controls [9,39]. The psychological well-being of patients with RA was found to be lower than healthy controls [40]. To our knowledge, ours is the first study evaluating the psychological well-being of AS patients using the PGWB score.

Many patients with rheumatological diseases are likely to be psychologically affected by the ongoing COVID-19 pandemic. Mancuso et al. reported that the psychiatric complaints of patients with rheumatological diseases (a total of 112 patients with Systemic Lupus Erythematosus (SLE), RA, and Spondyloarthritis) increased significantly during the pandemic [18]. On the other hand, Kucuk et al. found that patients with Behçet Disease were psychologically affected by the pandemic, and their PGWB scores were low compared to healthy controls, while the HADS anxiety and depression scores were significantly higher [19]. Tee et al. detected moderate levels of anxiety, depression, and stress in patients with RA during the pandemic [20] but reported that patients with SLE were affected more by the pandemic than patients with RA [20]. Similarly, Picchianti Diamanti et al. found that patients suffering from rheumatological diseases such as RA and AS experienced severe anxiety during the pandemic [21]. Interestingly, Seyahi et al. reported that patients with a rheumatologic disease had lower anxiety and depression levels than hospital workers in a large study involving hospital and academic staff [41]. Previous studies have already shown that healthcare workers experience a high degree of anxiety and fear [42,43]. In contrast to the study by Picchianti Diamanti et al. [21], the current study found that levels of perceived COVID threat between AS and

|                | BASDAI          | DAS28          |
|----------------|-----------------|----------------|
|                | r               | p              | r               | p              |
| PCTF           | 0.36            | 0.002          | 0.03            | 0.773          |
| PGWB           | −0.20           | 0.088          | −0.20           | 0.078          |
| SIS            | 0.57            | <0.001         | 0.21            | 0.063          |
| PACT           | −0.15           | 0.362          | −0.26           | 0.026          |
| PACT trauma-focused coping | −0.26 | 0.027 | 0.05 | 0.655 |
| PACT perceived forward-focused | 0.14 | 0.203 | 0.33 | 0.003 |
| HADS depression | 0.53 | <0.001 | 0.17 | 0.144 |
| HADS Anxiety   | 0.54            | <0.001         | 0.19            | 0.108          |

Pearson and spearman (rho) correlation tests were performed.

**Abbreviations:** BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, PCTF: perceived COVID-19 threat form, PGWB: psychological general well-being index, COVID-19: novel coronavirus 2019, SIS: suicide ideation scale, PACT: the perceived ability to cope with trauma scale, HADS: hospital anxiety and depression scale.
RA patients and healthy controls were similar. These data suggest that the healthy individuals who participated as controls in the study also perceived a similar level of threat of the COVID-19 pandemic as the patients. In our study, the general psychological well-being of patients with AS and RA was worse with higher complaints of anxiety and depression compared to healthy controls. Additionally, a correlation between perceived COVID threat and the suicidal ideation, level of depression, and anxiety were identified in patients with AS and RA suggesting that these patients were severely affected by the COVID-19 pandemic. In fact, the association of a perceived threat with distress and lower levels of well-being has been reported in previous studies conducted on healthy individuals [44]. Similarly, in population studies with large sample sizes, COVID-19 has been reported to increase the frequency of the presence of anxiety and depressive symptoms [45].

Whether the follow-up, treatment, and disease activity of rheumatological diseases changed during the pandemic has been the subject of many studies [46,47]. Lopez et al. investigated whether the disease activity scores of patients with RA and axial spondyloarthritis changed during the pandemic period and observed that 37.4% of the patients showed worsening of disease activity [46]. On the other hand, Ciurea et al. found that disease activity of patients with neither RA nor AS increased significantly during the COVID-19 pandemic [47]. The current study did not evaluate whether the disease activity of patients was affected by the pandemic directly. Rather, we found that AS patients with high-disease activity were more affected by the COVID-19 threat compared to patients with low-disease activity; their sense of well-being was lower, and their anxiety and depression scores were higher. At the same time, a significant relationship was found between the perceived threat of COVID-19 and disease activity in patients with AS. Suicidal ideation, ability to cope with trauma, anxiety and depressive symptoms were found to be related to disease activity in patients with AS. However, it was observed that only the ability to cope with trauma was associated with disease activity in patients with RA. There were no patients with severe RA in the current study. The score of coping with trauma was the only difference identified between moderate RA and mild RA cases. The fact that the proportion of AS patients with high-disease activity (68.75%) was higher than the proportion of AS patients with low-disease activity may suggest that patients with AS were more affected by the pandemic compared to patients with RA. Nonetheless, the lack of patients with severe RA may explain the absence of a significant relationship between RA disease activity and psychological parameters. On the other hand, it has been previously reported that psychological symptoms were higher in patients with AS compared to patients with RA [7]. Similarly, in previous studies, it has been reported that disease activity was associated with psychological status in patients with AS [9]. Different clinical courses, age of onset, and gender distributions of the two diseases may result in differences in psychological factors and symptoms. Levels of neurotransmitters such as serotonin and noradrenaline, which play a role in the pathophysiology of depression, anxiety, and pain, may also differ between patients with RA and AS [48–51]. Due to these differences, AS and RA patients may not be affected by the pandemic to the same extent.

An important outcome of the current study is the finding of a more pronounced negative correlation between coping skills and disease activity in patients with RA compared to patients with AS. A significant relationship between the perception of pain and inability to cope has previously been reported in patients with RA [52]. In the same study, it was emphasized that passive coping skills were predictors of both depression and pain in patients with RA, and because RA exacerbations are unpredictable, individuals with inadequate coping skills interpret the disease as uncontrollable [52].

In conclusion, the current study showed that patients with AS and RA displayed a worse psychological status compared to a healthy control group in response to the ongoing COVID-19 pandemic. While the perceived COVID-19 threat was related to most psychometric areas, both psychometric features and perceived COVID-19 threat were related to disease activity in patients with AS. In patients with RA, only the perception of coping with trauma was found to be associated with disease activity. Patients with AS may be more vulnerable to the psychological effects of the pandemic, which can affect disease activity.

**Funding sources**
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Informed consent**
Prior to the start of the study, all participants received an informed consent form stating the details of the research, and participants who consented to volunteer approved this form. The Turkish Ministry of Health, General Directorate of Health Services approved the study protocol (Approval Date/Number: 29.04.2020/SAKRIR GICA-2020-04-29-T16_26_23). The local Ethics Committee on human research also approved the study (IRB Date/Number: 08.05.2020/2020-2485).
References

1. Akhondi H, Varacallo M. Rheumatoid arthritis and ankylosing spondylitis. Treasure Island, FL, USA: StatPearls Publishing; 2020.

2. Barlow JH, Macey SJ, Struthers GR. Gender, depression and ankylosing spondylitis. Arthritis Care & Research 1993; 6: 45-51.

3. Ben Tekaya A, Mahmoud I, Hamdi I, Hechmi S, Saïdane O et al. Depression and anxiety in spondyloarthritis: prevalence and relationship with clinical parameters and self-reported outcome measures. Turkish Journal of Psychiatry 2019; 30: 90-98.

4. Isik A, Koca SS, Ozturk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. Clinical Rheumatology 2007; 26: 872–878.

5. Marrie RA, Hitchon CA, Wallr D, Patten SB, Bolton JM et al. increased burden of psychiatric disorders in rheumatoid arthritis. arthritis care & research (Hoboken). 2018; 70 (7): 970-978.

6. Nicassio PM. Arthritis and psychiatric disorders: disentangling the relationship. Journal of Psychosomatic Research 2010; 68 (2): 183-5. doi: 10.1016/j.jpsychores.2009.09.008

7. Sundquist K, Li X, Hemminki K, Sundquist J. Subsequent risk of hospitalization for neuropsychiatric disorders in patients with rheumatic diseases: a nationwide study from Sweden. Archives of General Psychiatry 2008; 65 (5): 501–507. doi:10.1001/ archpsyc.65.5.501

8. Durmus D, Sarısoy G, Alayli G, Kesmen H, Çetin E et al. Psychiatric symptoms in ankylosing spondylitis: their relationship with disease activity, functional capacity, pain and fatigue. Comprehensive Psychiatry 2015; 62: 170-177. doi: 10.1016/j. comppsych.2015.07.016

9. Baysal O, Durmuş B, Ersoy Y, Altay Z, Senel K et al. Relationship between psychological status and disease activity and quality of life in ankylosing spondylitis. Rheumatology International 2011; 31 (6): 795–800. doi: 10.1007/s00296-010-1381-x

10. Aktekin LA, Eser F, Başkan BM, Sivas F, Malhan S et al. Disability of Arm Shoulder and Hand Questionnaire in rheumatoid arthritis patients: relationship with disease activity, HAQ, SF-36. Rheumatology International 2011; 31 (6): 823-826. doi: 10.1007/s00296-010-1568-1

11. Brooks SK, Dunn R, Amlôt R, Rubin GJ, Greenberg N. A systematic, thematic review of social and occupational factors associated with psychological outcomes in healthcare employees during an infectious disease outbreak. Journal of Occupational and Environmental Medicine 2018; 60: 248-257.

12. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S et al. The psychological impact of quarantine and how to reduce it: A rapid review of the evidence. Lancet 2020; 395: 912-920. doi: https://doi.org/10.1016/S0140-6736(20)30460-8

13. Gica S, Kavaklı M, Durduran Y, Ak M. The Effect of COVID-19 Pandemic on psychosomatic complaints and investigation of the mediating role of intolerance to uncertainty, biological rhythm changes and perceived COVID-19 threat in this relationship: a web-based community survey. Psychiatry and Clinical Psychopharmacology 2020; 30 (2): 89-96. doi:10.5455/PCP.20200514033022

14. Sarısoy G, Durmuş D, Boke O, Cantürk F, Şahin AR. Coping with stress and body image in patients with ankylosing spondylitis. Archives of Neuropsychiatry 2014; 51: 110-115.

15. Fortinasit KM, Holoday-Worret P. Psychiatric mental health nursing. 5th ed. St. Louis, MO, USA: Mosby; 1996.

16. Ciureka A, Papagiannoulis E, Bürki K, von Loga I, Micheroli R et al. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases 2021; 80 (2): 238-241. doi: 10.1136/ annrheumdis-2020-218705

17. Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F et al. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. Lancet Rheumatology 2020; 2: e549-e56. doi: 10.1016/S2665-9913(20)30169-7

18. Mancuso CA, Duculan R, Jannat-Khah D, Barbhaiya M, Bass AR et al. Rheumatic disease-related symptoms during the height of the COVID-19 pandemic. HSS Journal 2020; 18: 1-9 [ahead of print]. doi:10.s11420-020-09798-8

19. Kucuk A, Vatansev H, Gica S, Demir S, Cure E. Effects of COVID-19 Pandemic on psychological condition and disease severity in patients with Behçet's Disease. Psychiatry and Behavioral Sciences 2020; 10 (4): 168-177. doi: 10.5455/PBS.20200913012956

20. Tee CA, Salido EO, Reyes PWC, Ho RC, Tee ML. Psychological state and associated factors during the 2019 coronavirus disease (COVID-19) pandemic among filipinos with rheumatoid arthritis or systemic lupus erythematosus. Open Access Rheumatology 2020; 12: 215-222. doi: 10.2147/OARRR.S269889

21. Picchianti Diamanti A, Cattaruzza MS, Di Rosa R, Del Porto F, Salemi S et al. Psychological distress in patients with autoimmune arthritis during the COVID-19 induced lockdown in Italy. Microorganisms 2020; 8 (11): 1818. doi: 10.3390/microorganisms8111818

22. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods 2007; 39: 175-191. https://doi.org/10.3758/BRM.41.4.1149

23. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behavior Research Methods 2009; 41: 1149-1160. https://doi.org/10.3758/BRM.41.4.1149

24. Kavaklı M, Ak M, Uğur F, Türkmen OO. The mediating role of self-compassion in the relationship between perceived COVID-19 threat and death anxiety. Turkish Journal of Clinical Psychiatry 2020; 23 (1): 15-23. doi: 10.5505/kp.2020.58962

25. Dilbaz N, Holat H, Bayam G, Berkson O, Holat H et al. Validity and reliability of suicide ideation scale. In: 31st Turkish National Congress of Psychiatry; İstanbul, Turkey. pp. 40-41. (In Turkish)
26. Aydemir O, Guvenir T, Kucy L, Kultur S. Reliability and validity of the Turkish version of Hospital Anxiety and Depression Scale. Turkish Journal of Psychiatry 1997; 8 (4): 280-287.

27. Bonanno GA, Pat-Horenczyk R, Noli J. Coping flexibility and trauma: The Perceived Ability to Cope with Trauma (PACT) scale. Psychological Trauma: Theory, Research, Practice, and Policy 2011; 3 (2): 117-129.

28. Ari E, Cesur-Soysal G. Perceived Ability to Cope with Trauma Scale (PACT): The Turkish adaptation, validity and reliability study. Journal of Clinical Psychology Research 2019; 3: 17-25.

29. Diener E, Wirtz D, Tov W, Kim-Prieto C, Choi D et al. New well-being measures: Short scales to assess flourishing and positive and negative feelings. Social Indicators Research 2010; 97: 143–156.

30. Telef BB. The Adaptation of Psychological Well-Being into Turkish: A validity and reliability study. Hacettepe University - Journal of Education 2013; 28 (3): 374-384.

31. Calin A, Nakache JP, Gueguen A, Zeidler H, Melants H et al. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 1999; 38 (9): 878-882.

32. Akkok Y, Karatepe AG, Akar S, Kirazli Y, Akkok N. A Turkish version of the bath ankylosing spondylitis disease activity index: reliability and validity. Rheumatology International 2005; 25 (4): 280-284.

33. van Riel PL, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clinical and Experimental Rheumatology 2016; 34 (Suppl 101): 40-44.

34. Tan YK, Li H, Allen JC Jr, Thumboo J. Anti-cyclic citrullinated peptide but not rheumatoid factor is associated with ultrasound-detected bone erosion among rheumatoid arthritis patients with at least moderate disease activity. International Journal of Rheumatic Disease 2020; 23 (10): 1337-1343. doi: 10.1111/1756-185X.13933

35. Nam B, Koo BS, Lee TH, Shin JH, Kim JJ et al. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study. BMC Musculoskelet Disorders 2021; 22 (1): 140. doi: 10.1186/s12891-020-03941-8

36. Kelly K. Ankylosing spondylitis and undifferentiated spondyloarthritis: The relationship between living with these diseases and psychological well-being. Musculoskeletal Care 2020 [ahead of print]. doi: 10.1002/msc.1513

37. Treharne GJ, Kitas GD, Lyons AC, Booth DA. Well-being in rheumatoid arthritis: the effects of disease duration and psychosocial factors. Journal of Health Psychology 2005; 10 (3): 457-74. doi: 10.1177/1359105305051416

38. Jobski K, Luque Ramos A, Albrecht K, Hoffmann E. Pain, depressive symptoms and medication in German patients with rheumatoid arthritis-results from the linking patient-reported outcomes with claims data for health services research in rheumatology (PROCLAIM) study. Pharmacoepidemiology and Drug Safe 2017; 26 (7): 766-774. doi: 10.1002/pds.4202

39. Bayram K, Erol A. Childhood traumatic experiences, anxiety, and depression levels in fibromyalgia and rheumatoid arthritis. Archives of Neuropsychiatry 2014; 51 (4): 344-349. doi:10.5152/npa.2014.6958

40. Valtyssöötti ST, Gudbjörnsson B, Hallgren R, Hetta J. Psychological well-being in patients with primary Sjögren’s syndrome. Clinical and Experimental Rheumatology 2000; 18 (5): 597-600.

41. Seyahi E, Poyraz BC, Sun T, Akdogan S, Hamuryudan V. The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey. Rheumatology International 2020; 22: 1-10 [ahead of print]. doi:10.1007/s00296-020-04626-0

42. Manzano García G, Ayala Calvo JC. The threat of COVID-19 and its influence on nursing staff burnout. Journal of Advanced Nursing 2020 [ahead of print]. doi: 10.1111/jan.14642

43. Spoorthy MS, Pratapa SK, Mahant S. Mental health problems faced by healthcare workers due to the COVID-19 pandemic-A review. Asian Journal of Psychiatry 2020; 51: 102119. doi:10.1016/j.ajp.2020.102119

44. KachanoﬀFJ, Bigman YE, Kapssakis K, Gray K. measuring realistic and symbolic threats of COVID-19 and their unique impacts on well-being and adherence to public health behaviors. Social Psychological and Personality Science 2020 [ahead of print]. doi:10.1177/1948550620931634

45. Dawel A, Shou Y, Smithson M, Cherbuin N, Banfield M et al. The Effect of COVID-19 on mental health and well-being in a representative sample of Australian Adults. Front Psychiatry 2020; 11: 579985. doi: 10.3389/fpsyg.2020.579985

46. López-Medina C, Ladehesa-Pineda L, Gómez-Garcia I, Ángeles Puche-Larrubia M, Miguel Seguí-Sabater J et al. Treatment adherence during the COVID-19 pandemic and the impact of confinement on disease activity and emotional status: a survey in 644 rheumatic patients. Joint Bone Spine 2020; 27: 105085 [ahead of print]. doi:10.1016/j.jbspin.2020.105085

47. Ciurea A, Papagiannoulis E, Bürkki K, Von Loga I, Micheroli R et al. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases 2020; 0: 1-4 [ahead of print]. doi:10.1136/annrheumdis-2020-218705

48. Woo AK. Depression and anxiety in pain. Reviews in Pain 2010; 4 (1): 8-12. doi:10.1177/204946371000400103

49. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L et al. A meta-analysis of cytokines in major depression. Biological Psychiatry 2010; 67 (5): 446–457.

50. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nature Reviews Immunology 2016; 16 (1): 22–34.

51. Sheng J, Liu S, Wang Y, Cui R, Zhang X. The link between depression and chronic pain: neural mechanisms in the brain. Neural Plasticity 2017; 2017: 9724371. doi: 10.1155/2017/9724371

52. Covic T, Adamson B, Hough M. The impact of passive coping on rheumatoid arthritis pain. Rheumatology (Oxford) 2000; 39 (9): 1027-1030. doi: 10.1093/rheumatology/39.9.1027